Curing Opioid Toxicity with Intrathecal Targeted Drug Delivery

Pain is one of the most feared symptoms that concern cancer patients and their families. Despite well-established guidelines set forth by the World Health Organization (WHO) on the treatment of cancer pain, nearly half of cancer patients report poorly controlled pain. One of the most serious side ef...

Full description

Saved in:
Bibliographic Details
Main Authors: Thomas P. Pittelkow, Markus A. Bendel, Jacob J. Strand, Susan M. Moeschler
Format: Article
Language:English
Published: Wiley 2019-01-01
Series:Case Reports in Medicine
Online Access:http://dx.doi.org/10.1155/2019/3428576
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832549403932491776
author Thomas P. Pittelkow
Markus A. Bendel
Jacob J. Strand
Susan M. Moeschler
author_facet Thomas P. Pittelkow
Markus A. Bendel
Jacob J. Strand
Susan M. Moeschler
author_sort Thomas P. Pittelkow
collection DOAJ
description Pain is one of the most feared symptoms that concern cancer patients and their families. Despite well-established guidelines set forth by the World Health Organization (WHO) on the treatment of cancer pain, nearly half of cancer patients report poorly controlled pain. One of the most serious side effects of systemic oral opioid use is neurotoxicity, which is characterized by altered mental status and systemic neurologic impairments. Treatment strategies are supportive in nature and focused on reducing or changing the offending opioid and correcting any metabolic deficiencies. Herein, we discuss a case of opioid-induced neurotoxicity treated with intrathecal targeted drug delivery (TDD). The timing and implementation of advanced therapies such as intrathecal TDD is not well delineated. More importantly, patients and their oncologic providers are often unaware of this useful tool in treating challenging cancer-associated pain and significantly minimizing systemic opioid side effects. To ensure that patients have comprehensive oncologic care, best-practice guidelines suggest involvement of an interdisciplinary team and coordinated care. Early referral to a pain and palliative specialist may allow for improved patient outcomes and removal of unnecessary barriers to optimal patient care.
format Article
id doaj-art-c372747555bd47e4be76c1589110aa29
institution Kabale University
issn 1687-9627
1687-9635
language English
publishDate 2019-01-01
publisher Wiley
record_format Article
series Case Reports in Medicine
spelling doaj-art-c372747555bd47e4be76c1589110aa292025-02-03T06:11:28ZengWileyCase Reports in Medicine1687-96271687-96352019-01-01201910.1155/2019/34285763428576Curing Opioid Toxicity with Intrathecal Targeted Drug DeliveryThomas P. Pittelkow0Markus A. Bendel1Jacob J. Strand2Susan M. Moeschler3Division of Pain Medicine, Department of Anesthesiology and Perioperative Medicine, Mayo Clinic College of Medicine and Science, 200 First Street SW, Rochester, MN 55905, USADivision of Pain Medicine, Department of Anesthesiology and Perioperative Medicine, Mayo Clinic College of Medicine and Science, 200 First Street SW, Rochester, MN 55905, USACenter for Palliative Medicine, Department of Medicine, Mayo Clinic College of Medicine and Science, 200 First Street SW, Rochester, MN 55905, USADivision of Pain Medicine, Department of Anesthesiology and Perioperative Medicine, Mayo Clinic College of Medicine and Science, 200 First Street SW, Rochester, MN 55905, USAPain is one of the most feared symptoms that concern cancer patients and their families. Despite well-established guidelines set forth by the World Health Organization (WHO) on the treatment of cancer pain, nearly half of cancer patients report poorly controlled pain. One of the most serious side effects of systemic oral opioid use is neurotoxicity, which is characterized by altered mental status and systemic neurologic impairments. Treatment strategies are supportive in nature and focused on reducing or changing the offending opioid and correcting any metabolic deficiencies. Herein, we discuss a case of opioid-induced neurotoxicity treated with intrathecal targeted drug delivery (TDD). The timing and implementation of advanced therapies such as intrathecal TDD is not well delineated. More importantly, patients and their oncologic providers are often unaware of this useful tool in treating challenging cancer-associated pain and significantly minimizing systemic opioid side effects. To ensure that patients have comprehensive oncologic care, best-practice guidelines suggest involvement of an interdisciplinary team and coordinated care. Early referral to a pain and palliative specialist may allow for improved patient outcomes and removal of unnecessary barriers to optimal patient care.http://dx.doi.org/10.1155/2019/3428576
spellingShingle Thomas P. Pittelkow
Markus A. Bendel
Jacob J. Strand
Susan M. Moeschler
Curing Opioid Toxicity with Intrathecal Targeted Drug Delivery
Case Reports in Medicine
title Curing Opioid Toxicity with Intrathecal Targeted Drug Delivery
title_full Curing Opioid Toxicity with Intrathecal Targeted Drug Delivery
title_fullStr Curing Opioid Toxicity with Intrathecal Targeted Drug Delivery
title_full_unstemmed Curing Opioid Toxicity with Intrathecal Targeted Drug Delivery
title_short Curing Opioid Toxicity with Intrathecal Targeted Drug Delivery
title_sort curing opioid toxicity with intrathecal targeted drug delivery
url http://dx.doi.org/10.1155/2019/3428576
work_keys_str_mv AT thomasppittelkow curingopioidtoxicitywithintrathecaltargeteddrugdelivery
AT markusabendel curingopioidtoxicitywithintrathecaltargeteddrugdelivery
AT jacobjstrand curingopioidtoxicitywithintrathecaltargeteddrugdelivery
AT susanmmoeschler curingopioidtoxicitywithintrathecaltargeteddrugdelivery